Pyroptosis-preconditioned mesenchymal stromal cell-derived extracellular vesicles as advanced nanomedicines for treating inflammatory diseases

Abstract

Uncontrolled inflammation is one of the major causes of various forms of tissue injury, and nanomedicines with immunoregulatory effects are needed. Mesenchymal stromal cell-derived extracellular vesicles (e.g., MSC-EVs) have been proposed as promising therapies, but the highly efficient generation of EVs with desirable properties is still a considerable challenge in this field. Here, we report that preconditioning MSCs with a critical immune process (pyroptosis) is a robust method for improving both the yield and anti-inflammatory potency of MSC-EVs. In brief, pyroptosis-preconditioned MSCs using a combined lipopolysaccharide (LPS) and adenosine triphosphate (ATP) stimulation showed elevated EV yields compared with those of MSCs cultured under normal conditions. Pyroptosis preconditioning upregulated multiple pathways (e.g., cell proliferation, DNA repair, and the immune response) in MSCs, leading to the enrichment of immunoregulatory cargos (e.g., PD-L2 and STC2) in MSC-EVs. In vitro, pyroptosis-preconditioned MSC-EVs (P-EVs) treatment has greater potential to suppress cytokine expression and cell death in pyroptotic macrophages than treatment with normal MSC-EVs (N-EVs). Compared with N-EV treatment, P-EV treatment showed superior potency in attenuating proinflammatory cell infiltration, cytokine/chemokine expression, resident tissue cell death, and the severity of pathological injury in different models of inflammatory diseases (acute lung or kidney injury), and these effects are likely the joint result of diverse functional cargos delivered by such EVs. This study highlights that pyroptosis preconditioning is a promising strategy for the highly efficient production of MSC-EVs with advanced therapeutic potential for treating diverse inflammatory diseases.

Graphical abstract: Pyroptosis-preconditioned mesenchymal stromal cell-derived extracellular vesicles as advanced nanomedicines for treating inflammatory diseases

Supplementary files

Article information

Article type
Paper
Submitted
11 Nov 2024
Accepted
26 Mar 2025
First published
27 Mar 2025

Biomater. Sci., 2025, Advance Article

Pyroptosis-preconditioned mesenchymal stromal cell-derived extracellular vesicles as advanced nanomedicines for treating inflammatory diseases

Q. Wu, S. Liu, M. Zhao, Y. Wang, K. Lv, J. Zhu and J. Liu, Biomater. Sci., 2025, Advance Article , DOI: 10.1039/D4BM01505C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements